GlassScriptPhysician profile
Joseph Defoto
NPI 1033149711
$13,266.29
in general payments reported to CMS, 2019-2025
25 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,134 · 2020: $1,365 · 2021: $1,671 · 2022: $1,628 · 2023: $1,927 · 2024: $2,666 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,468.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,567.46 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $3,966.52 | 2019-2025 | Biktarvy |
| Janssen Biotech, INC. | $710.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $524.83 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Emd Serono, INC. | $434.83 | 2019-2025 | Serostim |
| Napo Pharmaceuticals INC | $346.48 | 2019-2025 | Mytesi |
| Antares Pharma, INC. | $305.97 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Theratechnologies INC. | $211.80 | 2019-2025 | Egrifta, Trogarzo |
| Amgen INC. | $205.09 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $191.24 | 2022-2025 | Spravato |
| Neurocrine Biosciences, INC. | $147.48 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $132.41 | 2024-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $102.84 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $76.69 | 2022-2023 | Quviviq |
| Dynavax Technologies Corporation | $71.88 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $44.57 | 2020 | |
| Endo Pharmaceuticals INC. | $34.67 | 2019-2020 | |
| Janssen Products, LP | $31.49 | 2022 | |
| Hologic Sales and Service, LLC | $28.86 | 2025 | Panther Fusion |
| Alkermes, INC. | $28.48 | 2025 | Vivitrol |
| Boston Scientific Corporation | $28.41 | 2022 | |
| Dermira, INC. | $23.43 | 2019 | |
| Novo Nordisk INC | $21.58 | 2023 | Saxenda, Wegovy |
| Glaxosmithkline, LLC. | $17.08 | 2023 | Arexvy, Shingrix |
| Mylan Institutional INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Defoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.